# Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

> **NCT02013336** · PHASE1 · UNKNOWN · sponsor: **South Plains Oncology Consortium** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent or Refractory Solid Tumors
- Ewing Sarcoma
- Rhabdomyosarcoma
- Neuroblastoma
- Osteosarcoma

## Interventions

- **DRUG:** MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

## Key facts

- **NCT ID:** NCT02013336
- **Lead sponsor:** South Plains Oncology Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013336, "Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02013336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*